Radical radiotherapy with concurrent weekly cisplatin in loco-regionally advanced squamous cell carcinoma of the head and neck: a single-institution experience

Table 3 Significant factors in multivariate analysis for outcome measures

Prognostic factor	p-value	Hazard Ratio	95% Confidence Interval
*Local Control*
Stage grouping (III vs IV)	0.013	1.816	1.134 – 2.908
Primary site (oral vs non-oral)	0.001	0.648	0.497 – 0.845
No of CT cycles (less vs more)	0.038	0.643	0.424 – 0.977
*Loco-regional Control*
Stage grouping (III vs IV)	0.000	2.406	1.551 – 3.734
No of CT cycles (less vs more)	0.014	0.627	0.432 – 0.909
*Disease Free Survival*
Stage grouping (III vs IV)	0.000	2.640	1.707 – 4.081
No of CT cycles (less vs more)	0.016	0.642	0.447 – 0.922